Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus
Open Access
- 1 January 2012
- journal article
- research article
- Published by Wiley in Autoimmune Diseases
- Vol. 2012, 1-6
Abstract
Objective. Although two recent randomized placebo-controlled trials of rituximab (RTX) failed to demonstrate efficacy in systemic lupus erythematosus (SLE), clinicians continue to use off-label RTX for cases refractory to current treatments. We evaluated the effectiveness and safety of rituximab for patients with refractory SLE in Korea.Methods. We retrospectively analyzed multicenter patients treated with RTX in Korea.Results. 39 SLE patients treated with RTX were included in the following manner: lupus nephritis 43.6%, hematologic 33.3%, arthritis 7.8%, myositis 7.8%, and others 7.7%. All patients had responded poorly to at least one conventional immunosuppressive agent (mean, cyclophosphamide 43.6%, mycophenolate mofetil 48.7%, and other drugs) before RTX. Clinical improvements (complete or partial remission) occurred in patients with renal disease, hematologic disease, arthritis, myositis, and other manifestations at 6 months after RTX. The SLEDAI score was significantly decreased fromat baseline toat 6 months,at 12 months, andat 24 months after RTX (). Among 28 clinical responders, 4 patients experienced a relapse of disease atmonths. Infections were noted in 3 patients (7.7%).Conclusion. RTX could be an effective and relatively safe therapeutic option in patients with severe refractory SLE until novel B-cell depletion therapy is available.
Keywords
Funding Information
- Ministry of Health and Welfare (A080588)
This publication has 24 references indexed in Scilit:
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab studyArthritis & Rheumatism, 2012
- B cell biomarkers of rituximab responses in systemic lupus erythematosusArthritis & Rheumatism, 2011
- Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)Arthritis Research & Therapy, 2011
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- Reduced-dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletionArthritis & Rheumatism, 2010
- Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registryArthritis & Rheumatism, 2010
- The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trialsRheumatology International, 2010
- Off-label use of rituximab in systemic lupus erythematosus: a systematic reviewClinical Rheumatology, 2010
- Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 casesLupus, 2009
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood, 2009